文献速递系统性红斑狼疮

Filgotinib与Lanraplenib治疗狼疮膜性肾病的II期随机双盲多中心研究

Phase II, randomised, double-blind, multicentre study evaluating the safety and efficacy of filgotinib and lanraplenib in patients with lupus membranous nephropathy.
PubMed 文献 · RMD Open · 2020-01-01

这项II期随机双盲多中心试验评估了JAK1抑制剂filgotinib和脾酪氨酸激酶抑制剂lanraplenib在狼疮膜性肾病患者中的安全性与疗效。共9例患者随机接受filgotinib(n=5)或lanraplenib(n=4),主要终点为16周时24小时尿蛋白较基线的百分比变化。filgotinib组16周后24小时尿蛋白中位下降50.7%(n=4),耐受性良好;lanraplenib组样本量过小,结论有限。

要点

  • filgotinib组16周时24小时尿蛋白中位下降50.7%(n=4)。
  • filgotinib治疗耐受性良好,SELENA-SLEDAI评分保持稳定。
  • lanraplenib组仅1例完成16周,结论有限。

核心结论

  • 本研究样本量小,仅能得出有限结论;filgotinib治疗可能存在治疗获益,支持未来在狼疮膜性肾病患者中进一步研究filgotinib或其他JAK抑制剂。

研究设计与样本

  • 这是一项在美国15个中心开展的II期随机双盲试验,评估filgotinib或lanraplenib治疗狼疮膜性肾病的安全性与疗效。
  • 合格患者按1:1随机分组,盲法接受filgotinib或lanraplenib治疗最长52周。
  • 主要终点为基线至第16周24小时尿蛋白的百分比变化。
  • 共9例患者随机接受filgotinib(n=5)或lanraplenib(n=4)。
  • filgotinib组4例、lanraplenib组1例完成第16周。

主要发现

  • filgotinib治疗16周后24小时尿蛋白中位下降50.7%(n=4)。
  • SELENA-SLEDAI评分保持稳定。
  • filgotinib治疗耐受性良好。
  • 对lanraplenib治疗的结论有限。

关键数值与推荐

  • 主要终点:基线至第16周24小时尿蛋白的百分比变化。
  • filgotinib组16周时24小时尿蛋白中位下降50.7%(n=4)。
  • SELENA-SLEDAI评分保持稳定。

临床怎么用

  • 目前证据仅来自小样本II期试验,尚不足以支持filgotinib或lanraplenib在狼疮膜性肾病中的常规临床应用。
  • 结果提示filgotinib可能有治疗获益,可考虑在临床试验框架下进一步评估JAK抑制剂用于狼疮膜性肾病。

局限性

  • 研究纳入患者数量少,仅能得出有限结论。
  • lanraplenib组完成16周者仅1例,相关结论有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Patients with lupus membranous nephropathy (LMN) are at risk for prolonged proteinuria and progressive chronic kidney disease. There are no proven effective treatments for LMN, and controlled trials are lacking. This trial assessed the preferential Janus kinase 1 (JAK1) inhibitor filgotinib and the spleen tyrosine kinase inhibitor lanraplenib in patients with LMN. METHODS: This was a phase II, randomised, double-blind trial conducted at 15 centres in the USA to evaluate the safety and efficacy of filgotinib or lanraplenib for the treatment of LMN. Eligible patients were randomised 1:1 to receive either filgotinib or lanraplenib in a blinded fashion for up to 52 weeks. The primary endpoint was the per cent change in 24-hour urine protein from baseline to week 16. RESULTS: Nine patients were randomised to receive filgotinib (n=5) or lanraplenib (n=4). Four patients in the filgotinib group and one patient in the lanraplenib group completed week 16. There was a median reduction of 50.7% in 24-hour urine protein after 16 weeks of treatment with filgotinib (n=4), and the median Systemic Lupus Erythematosus Disease Activity Index from the Safety of Estrogens in Lupus National Assessment score remained stable. Filgotinib treatment was well tolerated. Limited conclusions can be drawn about treatment with lanraplenib. CONCLUSION: The number of patients treated in this study was small, and only limited conclusions can be drawn. There may be a therapeutic benefit with filgotinib treatment, which may support future investigations with filgotinib or other JAK inhibitors in patients with LMN. TRIAL REGISTRATION NUMBER: NCT03285711.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Baker M, Chaichian Y, Genovese M, et al. Phase II, randomised, double-blind, multicentre study evaluating the safety and efficacy of filgotinib and lanraplenib in patients with lupus membranous nephropathy. RMD Open. 2020. PMID: 33380521. doi:10.1136/rmdopen-2020-001490

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。